Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
SAN DIEGO, May 08, 2017 -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months ended March 31, 2017, before the opening of trading on Monday, May 15, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Monday, May 15. The call will be open on a listen-only basis to any interested parties. The company will also provide a business update, including details on independent and partnered development programs in the conference call and webcast.
Conference Call
To listen to the conference call, dial in approximately ten minutes before the scheduled call to (719) 325-2361 (preferred), or (888) 466-4462 (toll-free), and reference confirmation code 9047479. A replay of the call will be available for 48 hours beginning about two hours after the call. To listen to the replay, dial (719) 457-0820 (preferred) or (888) 203-1112 (toll-free) and enter replay passcode 9047479. The call also will be available live and archived through the events page at www.vical.com.
Invited participants may ask questions during the conference call. Others may submit questions before the call by e-mail addressed to [email protected] or by fax to (858) 646-1150. Submitted questions will be screened for appropriateness and general interest. Selected questions received with sufficient notice before the call will be answered as time permits at the end of the call. For further information, contact Vical’s Investor Relations department by phone at (858) 646-1127 or by email at [email protected].
About Vical
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at www.vical.com.
Contact: Andrew Hopkins (858) 646-1127 Website: www.vical.com
